Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 1051 to 1060 of 1349 total matches.
TNF Inhibitors for Crohn's Disease: When, Which, and for How Long
The Medical Letter on Drugs and Therapeutics • Dec 23, 2013 (Issue 1432)
) – are approved by the FDA
for treatment of moderately to severely active Crohn’s
disease in adults who have had ...
Three tumor necrosis factor (TNF) inhibitors – infliximab
(Remicade), adalimumab (Humira), and certolizumab
pegol (Cimzia) – are approved by the FDA
for treatment of moderately to severely active Crohn’s
disease in adults who have had an inadequate
response to conventional therapy. Infliximab is also
FDA-approved for the same indication in children ≥6
years old and for treatment of fistulas in adults. All 3
TNF inhibitors have been shown to reduce the signs
and symptoms of Crohn's disease in clinical trials.
They have been associated with adverse effects such
as...
Extended-Release Oxycodone and Acetaminophen (Xartemis XR)
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014 (Issue 1447)
the active ingredients at a steady rate over
an extended period. Oxycodone plasma concentrations
Extended ...
The FDA has approved a fixed-dose extended-release
formulation of oxycodone and acetaminophen
(Xartemis XR – Mallinckrodt) for oral treatment of
acute pain severe enough to require an opioid. Oxycodone
is available in the US as a single entity in oral
immediate-release (Oxecta, and others) and extendedrelease
(OxyContin) formulations. Immediate-release
oxycodone is also available in combination with aspirin
(Percodan, and others), acetaminophen (Percocet,
and others), or ibuprofen (see Table 1).
Eluxadoline (Viberzi) for Irritable Bowel Syndrome with Diarrhea
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016 (Issue 1485)
and other drugs that reduce GI motility, such
as anticholinergics or systemically active opioids,
could result ...
The FDA has approved eluxadoline (Viberzi – Actavis),
a mu-opioid receptor agonist and delta-opioid
receptor antagonist, for oral treatment of adults with
irritable bowel syndrome with diarrhea (IBS-D).
A New Abuse-Deterrent Opioid - Xtampza ER
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016 (Issue 1497)
). Patients
treated with the active drug had significantly lower
pain scores from week 2-12 than those who ...
The FDA has approved Xtampza ER (Collegium),
a new extended-release, abuse-deterrent capsule
formulation of oxycodone, for management of pain
severe enough to require daily, around-the-clock,
long-term opioid treatment and for which alternative
treatment options are inadequate.
Two New Amphetamines for ADHD
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016 (Issue 1497)
/day) of the new suspension over 5 weeks,
followed by 1 week of treatment with either the active drug ...
Two new extended-release amphetamine products
have been approved by the FDA for once-daily
treatment of attention-deficit/hyperactivity disorder
(ADHD) in patients ≥6 years old: Adzenys XR-ODT
(Neos Therapeutics), an orally distintegrating tablet,
and Dyanavel XR (Tris Pharma), an oral suspension.
Abuse-Deterrent Opioids
The Medical Letter on Drugs and Therapeutics • Jun 05, 2017 (Issue 1522)
manipulation should then be conducted.
Based on these results, a randomized, doubleblind,
placebo- and active ...
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and
public health advocates. Since our last article on
this subject, several new abuse-deterrent opioid
formulations have been approved by the FDA,
including an oxycodone tablet formulation (Roxybond
– Inspirion) that is the first immediate-release opioid
product FDA-approved to include claims of abuse
deterrence in its labeling. No opioid formulation
prevents consumption of a large number of intact
dosage units, the most common method of...
Hydrogen Peroxide 40% (Eskata) for Seborrheic Keratoses
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018 (Issue 1556)
, all 4 lesions
were graded clear in 4% and 8% of patients treated with
the active drug (see Table 1 ...
The FDA has approved hydrogen peroxide 40% topical
solution (Eskata – Aclaris Therapeutics) for treatment
of raised seborrheic keratoses (SKs) in adults. It is the
first drug to be approved for this indication. (Hydrogen
peroxide is available over the counter for topical use
as a 3% solution.)
Brexanolone (Zulresso) for Postpartum Depression
The Medical Letter on Drugs and Therapeutics • May 06, 2019 (Issue 1571)
for treatment of refractory PPD.1
PHARMACOLOGY — Brexanolone positively modulates
neuronal activation ...
The FDA has approved the GABAA receptor modulator
brexanolone (Zulresso – Sage Therapeutics) for
IV treatment of postpartum depression (PPD).
Brexanolone is the first drug to be approved by the FDA
for this indication.
Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
is readily absorbed through the nasal mucosa. It
activates glucagon receptors in the liver, stimulating ...
The FDA has approved glucagon nasal powder
(Baqsimi – Lilly) for treatment of severe hypoglycemia
in patients ≥4 years old with diabetes. Baqsimi is the
first noninjectable glucagon formulation to become
available in the US. Injectable glucagon emergency kits
(GlucaGen Hypokit, and generic) have been available
for years, but they require reconstitution of the
lyophilized powder by the caregiver immediately before
injection. An injectable glucagon formulation that does
not require reconstitution was recently approved by the
FDA (Gvoke) and is expected to become available...
COVID-19 Updates
The Medical Letter on Drugs and Therapeutics • Apr 18, 2022 (Issue 1648)
to be effective for treatment of COVID-19
caused by BA.2; it has significantly less neutralizing
activity ...
The FDA has expanded the Emergency Use Authorizations
(EUAs) for the mRNA COVID-19 vaccines
manufactured by Pfizer-BioNTech (Comirnaty) and
Moderna (Spikevax) to allow for their use as a second
booster dose ≥4 months after a first booster dose in
adults ≥50 years old and in persons aged ≥12 years
(Pfizer) or ≥18 years (Moderna) who have undergone
solid organ transplantation or have a condition that
compromises the immune system to a similar extent.